Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,843 total articles
I previously expected a tougher near-term outlook for Vertex, but a reassessment of valuation, cash flow, and the strategic $10B Crinetics acquisition convinces me to flip to a constructive stance. Trade plan: enter at $506.52, stop $470, target $600 over 180 trading days.
Red Violet (RDVT) is a small but profitable provider of cloud-based, mission-critical information tools (IDI, Forewarn) showing 20% quarterly revenue growth and $90.3M in annual sales. With improving technicals, a clean balance sheet, and $100M in recent gross proceeds from an at-the-money offering, the risk/reward supports a long trade aimed at a …
<p>Baidu trades at a sub-1 PB and a market cap of roughly $33.97B, but weakening technicals, heavy short activity, and tougher-to-defend AI/cloud monetization assumptions make the stock vulnerable over the next several weeks. This idea is a tactical short with a clearly defined entry, stop and target and a mid-term horizon of 45 trading days.</p>
Meta Platforms appears to carry roughly $27 billion of value that is not fully reflected in its balance sheet or share price today. That implicit value — in the form of strategic minority investments, marketable securities and repurchase optionality — creates an asymmetric risk-reward for a long trade. The plan below lays out an entry, stop and tar…
Super Micro (SMCI) posted blowout AI-driven revenue growth and margin improvement but remains discounted after a period of intense scrutiny and dilution fears. With market cap near $25B, EV/Sales under 1x and a crowded short base, the market is pricing a much darker scenario than fundamentals currently imply. This trade targets a recovery once orde…
Hims & Hers (HIMS) faces a regulatory and margin squeeze but has clear levers to recapture gross margin and control growth: bring higher-margin production in-house, integrate Eucalyptus, and monetize diagnostics and telehealth scale. This trade lays out an actionable long with entry at $29.00, a stop loss at $24.00 and a target of $40.00 tied to ma…
Microsoft sits at the center of the enterprise AI boom: massive cloud scale, sticky SaaS cash flow, and a fortress balance sheet. At $496.84 the stock looks like a high-quality, mid-priced entry into AI exposure — not the cheapest, but one of the safest ways to play large-scale generative AI adoption. This trade plan lays out an entry, stop, and ta…
Sky Harbour builds and leases private aviation hangars. With a market cap near $883M, improving momentum, and high short interest, the stock offers a speculative long opportunity for patient traders willing to accept elevated operational and leverage risk. Entry $10.98, stop $9.00, target $15.00. Long-term (180 trading days) plan.
Sandisk's sharp sell-off in July created an actionable entry for traders. The company still sits on massive AI-driven demand visibility, attractive cash flows and a heavy buyback; this trade targets a recovery toward prior highs while using a tight stop to protect from cyclical downside.
Applied Materials pulled back sharply from its highs, presenting a tradeable entry for disciplined longs. The business sits squarely in the AI-driven semiconductor capex cycle, posts healthy free cash flow, and carries modest leverage. Valuation is premium, so risk control and staged targets are essential.
Duolingo is intentionally sacrificing short-term revenue growth to chase 100 million daily active users (DAU) by 2028. With 56.5M DAU today, 27% revenue growth, $407.9M free cash flow and a $6.74B market cap, the risk/reward looks asymmetric for a mid-term long swing if DAU acceleration resumes. This trade lays out a clear entry at $144.0547, a $22…
Palantir's latest quarter made skeptics uncomfortable: 93% revenue growth, a pronounced commercial acceleration and a sharp margin expansion. Technical momentum, declining short interest and ample free cash flow create a favorable set-up for a mid-term long. This trade plan outlines an entry at $175.00, a stop at $160.00 and a target of $220.00 ove…
FirstCash is uniquely positioned to convert macro stress and recent UK acquisitions into outsized earnings and free cash flow growth. At roughly $210 per share today, the stock offers a 5.8% FCF yield and room for multiple expansion as scale, operating leverage and cross-border synergies materialize. This trade idea lays out an entry at $211.00, a …
IperionX ($IPX) is executing on a clear strategy: convert domestic titanium scrap into low-carbon titanium powders, lock up feedstock, and run customer qualification programs that can underpin premium pricing and long-term offtakes. Recent steps - most notably the June acquisition of adjacent Camden assets for $3.0M - materially reduce feedstock ri…
AIXTRON supplies deposition equipment critical to GaN, SiC and photonic device manufacturing. Technicals show stabilizing momentum while short interest and short-volume metrics signal a crowded trade that could flip into a squeeze. This trade idea runs long with a clear entry at $48.00, stop at $40.00 and a 180-trading-day target of $72.00.
AMD trades at a premium P/E but its AI and data-center momentum, improving profitability and strong free cash flow justify holding through near-term multiple compression. This trade targets a disciplined entry at $487 with a $560 target and $440 stop, sized for an investor comfortable with medium risk over a 180-trading-day horizon.
Alphabet is trading at $344 with a $4.21 trillion market cap. YouTube - part of Google Services - is driving structural ad revenue gains, creator monetization, and AI data advantages that justify a measured long. Trade plan: enter $344.00, stop $320.00, target $420.00 over a long-term window (180 trading days).
Timken has rallied but fundamentals still back further upside. Buy a measured pullback to $125, stop $119, target the 52-week high at $146.37 with a secondary target at $160. Trade horizon: mid term (45 trading days).
Broadcom's mix of semiconductor solutions and infrastructure software leaves it uniquely positioned to benefit from hyperscaler XPU builds and the optics/networking shift inside AI data centers. Financials show robust cash generation (free cash flow $32.8B) and an EPS base ($6.16) that recent results suggest can re-rate into faster growth. The stoc…
Trupanion has finally returned to GAAP profitability and continues to scale claims and subscription volume, but the share price already prices in flawless execution. With a market cap near $1.65B, a P/E around 57 and EV/EBITDA ~32, I view the stock as too expensive for a fresh long. This piece lays out a tactical short trade over the next ~45 tradi…
Intuitive Machines (LUNR) is trading on optimism tied to a $1.1B backlog, fresh NASA award news, and accelerating revenue, yet capital raises and negative free cash flow remain real drags. This trade targets a controlled long entry on a pullback to $16.00 with a $30.00 target over a mid-term window (45 trading days) and a $13.50 stop. The plan bala…
PSH (PGIM Short Duration High Yield ETF) sits at the intersection of attractive cash yield and low duration risk. With a 30-day SEC yield of 5.27% and a distribution yield near 5.95%, PSH is a practical vehicle to pick up carry while limiting rate-volatility exposure. Technicals show mild bullish momentum and a clear upside target at the 52-week hi…
U.S. Gold Corp. (USAU) is trading well below a feasibility-study implied valuation despite strong project economics, ample cash and clear catalysts in 2026. The market appears to be penalizing the stock for execution risk; this trade targets that gap with a mid-term long plan, defined entry, stop and target and a balanced risk framework.
Ultragenyx (RARE) is trading well below its 52-week high after clinical setbacks and legal headlines. The company’s commercial franchise (Crysvita, Mepsevii, Dojolvi, Evkeeza) produces recurring revenue, its balance sheet shows operational leverage, and current market pricing (~$2.8B market cap) underestimates binary upside from two upcoming FDA de…
Alamar (ALMR) is executing a classic instrument-plus-consumables model with a twist: it is building an open, research-grade proteomics dataset that can accelerate demand for its NULISA assays and ARGO instruments. The stock trades like a high-growth research name; the trade here is to buy into momentum and the expanding data moat while protecting c…
